ENGN enGene Holdings Inc.
USHealthcareAs of 2026-07-10 16:00
Why ENGN matters now
enGene Holdings Inc. (ENGN) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.90 with -1.04% on the session and $97.3M in market capitalization; recent performance reads 1-month +12.42% and YTD -80.95%.
The latest financial table shown here is Q2 2026, with revenue of $0.00, net income of $30.2M, and EPS of $0.43. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -126.5%.
The latest indexable market news headline is "enGene Reports Second Quarter 2026 Financial Results and Provides Business Update" from Business Wire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $3.50; recent insider activity includes Zoth Lota S. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.47
P/S
0.00
EV/EBITDA
-0.53
DCF Value
$0.28
FCF Yield
-126.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-29.3%
ROA
-21.6%
ROIC
-23.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $30.2M | $0.43 |
| Q1 2026 | $0.00 | $-29.8M | $-0.44 |
| Q4 2025 | $0.00 | $-37.9M | $-0.74 |
| FY 2025 | $0.00 | $-117.3M | $-2.29 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$6.13
Target (Median)
$3.50
Target Range
$2.00 - $28.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
-0.29
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.